GLAXOSMITHKLINE$44.48
+0.30
| Last Trade: |
44.48 |
| Trade Time: |
May 21 5:27 PM Eastern Daylight Time |
| Change: |
0.30 (0.68 %) |
| Prev Close: |
44.18 |
| Open: |
44.39 |
| Bid: |
43.45 |
| Ask: |
44.94 |
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
-
It was revealed on Thursday that Human Genome Sciences (NASDAQ: HGSI) is in talks with, in its own words "major" pharmaceutical and biotechnology companies in a bid to do whatever it can to avoid a ho ...
Read More »
-
Wednesday, May 9, 2012
It's all about Greece. Today's trading action may not be as volatile as the one on Tuesday, but the end result may not be much different. With the domestic news flow ...
Read More »
-
It's a sad fact that diabetes is becoming an increasingly commonplace disease, so at least it's encouraging that cutting-edge companies like the one featured below are making it a bit more easy to ...
Read More »
-
The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before Eli Lilly sees an extended period of steady, sustainable sales growth.
Read More »
-
There’s no one place for growth any longer, so it pays to diversify across world markets and few funds do it better than this one, says David West of Money Reporter.
At the Money Reporter, we ...
Read More »
-
When the pharmaceutical giant GlaxoSmithKline stepped up to the plate with a $13 a share offer for Human Genome Sciences, the subsequent rejection of the deal came as a bit of a surprise.
Read More »
Free Reports
|
|
